Role of hyperhomocystinemia in retinal vascular occlusive disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 1, 2007, Pages 104-107

  Sottilotta, Gianluca ^a   Oriana, Vincenzo ^a   Latella, Caterina ^a   Luise, Francesca ^a   Piromalli, Angela ^a   Ramirez, Francesca ^a   Mammi, Corrado ^a   Occhiuto, Antonio ^a   Lombardo, Vincenzo Trapani ^a,b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Homocysteine; Retinal vascular occlusive disease; Risk factor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; MALE; PREVALENCE; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FASTING; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PREVALENCE; RETINAL ARTERY OCCLUSION; RETINAL VEIN OCCLUSION; RISK FACTORS; THROMBOPHILIA;

EID: 33845402417     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606296423     Document Type: Article

References (11)

1. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001 ; 86 (3). 772-772.
2. Bick RL. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 2003 ; 17 (1). 115-115.
3. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997 ; 90 (1). 1-1.
4. Wirta V, Saransaari P, Wirta O, et al. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia and occlusive retinal vascular disease in type 2 diabetic and non-diabetic subjects. Clin Nephrol 2002 ; 58 (3). 171-171.
5. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000 ; 84 (2). 154-154.
6. Yildirim C, Yaylali V, Tatlipinar S, et al. Hyperhomocystinemia: A risk factor for retinal vein occlusion. Ophthalmologica 2004 ; 218 (2). 102-102.
7. Di Crecchio L, Parodi MB, Sanguinetti G, et al. Hyperhomocystinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology 2004 ; 111 (5). 940-940.
8. Boyd S, Owens D, Gin T, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001 ; 85 (11). 1313-1313.
9. Haas S. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients. Semin Thromb Hemost 1999 ; 25: 101-101.
10. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997 ; 20: 295-295.
11. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocysteinaemia. Lancet 1998 ; 351 (9098). 263-263.